Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

IL-18 signaling helps mature Tregs move into the thymus.

Keratin 19 expression in certain skin cells is temporary and not a reliable stem cell marker.

CD8+ T cells drive alopecia areata, while regulatory T cells are protective.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

Targeting specific T cells may help treat alopecia areata.

Autoimmune diseases need combined therapy of tolerance induction and immunosuppression.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Memory T cells in the skin balance staying put and moving into the blood, clustering around hair follicles, and increasing in number after infection.

Tislelizumab can cause cutaneous lupus erythematosus.

The role of γδT-cells in causing alopecia areata remains unclear.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

A specific type of immune cell plays a key role in causing alopecia areata and could be a target for treatment.

Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Folliculotropic mycosis fungoides has unique molecular features and cell interactions that could guide targeted therapy.

Tocilizumab might be an effective treatment for COVID-19.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

γδTregs may help treat autoimmune diseases like alopecia areata by promoting hair regrowth and reducing immune attacks.

γδ T cells can prevent and treat alopecia areata, offering a new therapy option.

CD18-deficient mice developed psoriasis-like skin disease, useful for studying inflammatory skin disorders.

CD4 T cells can cause alopecia areata by activating CD8 T cells to attack hair follicles.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

A man's skin cancer improved and some of his hair grew back after treatment with a special light therapy and a medication.